SCHEMBL7345209

SCHEMBL7345209

COC(=O)c1ccc2c(N)c(C#N)ccc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 1/20 0.54
KDM4E B2RXH2 3/20 0.45
ALDH1A1 P00352 3/20 0.45
MAPT P10636 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
MAP4K1 Q92918 1/20 0.44
GAA P10253 2/20 0.44
HPGD P15428 2/20 0.44
GLA P06280 1/20 0.44
CASP1 P29466 1/20 0.44
CASP7 P55210 1/20 0.44
ATM Q13315 1/20 0.44
HSD17B10 Q99714 1/20 0.44
ALOX15 P16050 1/20 0.43
HTT P42858 1/20 0.43
PTPN11 Q06124 1/20 0.43
USP2 O75604 1/20 0.42
CYP19A1 P11511 1/20 0.41
CYP11B1 P15538 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7590376 0.79 PTPN11 (0.53) LCKKDM4EALDH1A1MAPTSMN1; SMN2
SCHEMBL4950780 0.79 KDM4E (0.60) KDM4EALDH1A1MAPTSMN1; SMN2GAA
SCHEMBL7336521 0.79 LCK (0.49) LCKALDH1A1MAPTSMN1; SMN2HPGD
SCHEMBL4948601 0.78 LCK (0.57) LCKKDM4EALDH1A1MAPTGAA
SCHEMBL615318 0.77 LCK (0.52) LCKKDM4EALDH1A1MAPTSMN1; SMN2
SCHEMBL8148281 0.77 CA1 (0.52) KDM4EALDH1A1MAPTSMN1; SMN2GAA
SCHEMBL3446199 0.76 KDM4E (0.56) KDM4EALDH1A1MAPTSMN1; SMN2GAA
SCHEMBL5695700 0.76 PTPN11 (0.47) LCKALDH1A1MAPTSMN1; SMN2GAA
SCHEMBL7348003 0.74 NQO2 (0.46) LCKKDM4EALDH1A1SMN1; SMN2ALOX15
SCHEMBL2427132 0.74 CA1 (0.62) LCKKDM4EALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 LCK 3202/4885KDM4E 4285/4885ALDH1A1 920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.